Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study.

Mehlman C, Cadranel J, Rousseau-Bussac G, Lacave R, Pujals A, Girard N, Callens C, Gounant V, Théou-Anton N, Friard S, Trédaniel J, Blons H, Dujon C, Duchemann B, Schischmanoff PO, Chinet T, Giroux Leprieur E.

Lung Cancer. 2019 Nov;137:149-156. doi: 10.1016/j.lungcan.2019.09.019. Epub 2019 Sep 28.

PMID:
31600593
2.

Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors.

Hendriks LEL, Bootsma G, Mourlanette J, Henon C, Mezquita L, Ferrara R, Audigier-Valette C, Mazieres J, Lefebvre C, Duchemann B, Cousin S, le Pechoux C, Botticella A, De Ruysscher D, Dingemans AC, Besse B.

Eur J Cancer. 2019 Jul;116:182-189. doi: 10.1016/j.ejca.2019.05.019. Epub 2019 Jun 13.

PMID:
31203193
3.

Spectacular improvement of lung computer tomography after treatment with EGFR tyrosine kinase inhibitor for miliary carcinomatosis.

Archer G, Duchemann B, Gaudry S, Tandjaoui-Lambiotte Y.

Intensive Care Med. 2019 Oct;45(10):1472-1473. doi: 10.1007/s00134-019-05607-z. Epub 2019 Mar 25. No abstract available.

PMID:
30911802
4.

Nivolumab-refractory patients with advanced non-small-cell lung cancer.

Costantini A, Fallet V, Corny J, Friard S, Chouaid C, Duchemann B, Giroux-Leprieur E, Taillade L, Doucet L, Brosseau S, Wislez M, Tredaniel J, Cadranel J.

Lung Cancer. 2019 Apr;130:128-134. doi: 10.1016/j.lungcan.2019.01.015. Epub 2019 Feb 14.

5.

Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.

Hendriks LEL, Henon C, Auclin E, Mezquita L, Ferrara R, Audigier-Valette C, Mazieres J, Lefebvre C, Rabeau A, Le Moulec S, Cousin S, Duchemann B, le Pechoux C, Botticella A, Ammari S, Gazzah A, Caramella C, Adam J, Lechapt E, Planchard D, De Ruysscher D, Dingemans AM, Besse B.

J Thorac Oncol. 2019 Jul;14(7):1244-1254. doi: 10.1016/j.jtho.2019.02.009. Epub 2019 Feb 16.

PMID:
30780002
6.

Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST.

Goldfarb L, Duchemann B, Chouahnia K, Zelek L, Soussan M.

EJNMMI Res. 2019 Jan 29;9(1):8. doi: 10.1186/s13550-019-0473-1.

PMID:
30694399
7.

Immunotherapy for LELC: Case Report and a Focused Review.

Darrason M, Martin A, Soussan M, Chouahnia K, Pailler MC, Boudabous H, Brillet PY, Bousquet G, Zelek L, Duchemann B.

Clin Lung Cancer. 2019 May;20(3):e393-e401. doi: 10.1016/j.cllc.2018.12.008. Epub 2018 Dec 21. Review.

PMID:
30691964
8.

[Can nivolumab be used safely in idiopathic pulmonary fibrosis?]

Duchemann B, Didier M, Pailler MC, Brillet PY, Kambouchner M, Uzunhan Y, Freynet O, Chouahnia K, Zelek L, Nunes H.

Rev Mal Respir. 2019 Feb;36(2):209-213. doi: 10.1016/j.rmr.2018.11.001. Epub 2019 Jan 24. French.

PMID:
30686563
9.

Circulating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patients.

Charrier M, Mezquita L, Lueza B, Dupraz L, Planchard D, Remon J, Caramella C, Cassard L, Boselli L, Reiners KS, Pogge von Strandmann E, Rusakiewicz S, Ferrara R, Duchemann B, Naigeon M, Pignon JP, Besse B, Chaput N.

Eur J Cancer. 2019 Feb;108:88-96. doi: 10.1016/j.ejca.2018.12.017. Epub 2019 Jan 14.

PMID:
30648633
10.

Obesity survival paradox in cancer patients: Results from the Physical Frailty in older adult cancer patients (PF-EC) study.

Pamoukdjian F, Aparicio T, Canoui-Poitrine F, Duchemann B, Lévy V, Wind P, Ganne N, Sebbane G, Zelek L, Paillaud E.

Clin Nutr. 2019 Dec;38(6):2806-2812. doi: 10.1016/j.clnu.2018.12.011. Epub 2018 Dec 13.

PMID:
30583963
11.
12.

Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.

Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, Leroy L, Duchemann B, Lefebvre C, Veillon R, Westeel V, Koscielny S, Champiat S, Ferté C, Planchard D, Remon J, Boucher ME, Gazzah A, Adam J, Bria E, Tortora G, Soria JC, Besse B, Caramella C.

JAMA Oncol. 2018 Nov 1;4(11):1543-1552. doi: 10.1001/jamaoncol.2018.3676.

13.

Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer.

Costantini A, Corny J, Fallet V, Renet S, Friard S, Chouaid C, Duchemann B, Giroux-Leprieur E, Taillade L, Doucet L, Nguenang M, Jouveshomme S, Wislez M, Tredaniel J, Cadranel J.

ERJ Open Res. 2018 Apr 20;4(2). pii: 00120-2017. doi: 10.1183/23120541.00120-2017. eCollection 2018 Apr.

14.

Assessing cognitive function in patients treated with immune checkpoint inhibitors: A feasibility study.

Cuzzubbo S, Belin C, Chouahnia K, Baroudjian B, Duchemann B, Barlog C, Coarelli G, Ursu R, Poirier E, Lebbe C, Carpentier AF.

Psychooncology. 2018 Jul;27(7):1861-1864. doi: 10.1002/pon.4725. Epub 2018 Apr 19. No abstract available.

PMID:
29624771
15.

Identification of a discriminative metabolomic fingerprint of potential clinical relevance in saliva of patients with periodontitis using 1H nuclear magnetic resonance (NMR) spectroscopy.

Rzeznik M, Triba MN, Levy P, Jungo S, Botosoa E, Duchemann B, Le Moyec L, Bernaudin JF, Savarin P, Guez D.

PLoS One. 2017 Aug 24;12(8):e0182767. doi: 10.1371/journal.pone.0182767. eCollection 2017.

16.

Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris.

Duchemann B, Annesi-Maesano I, Jacobe de Naurois C, Sanyal S, Brillet PY, Brauner M, Kambouchner M, Huynh S, Naccache JM, Borie R, Piquet J, Mekinian A, Virally J, Uzunhan Y, Cadranel J, Crestani B, Fain O, Lhote F, Dhote R, Saidenberg-Kermanac'h N, Rosental PA, Valeyre D, Nunes H.

Eur Respir J. 2017 Aug 3;50(2). pii: 1602419. doi: 10.1183/13993003.02419-2016. Print 2017 Aug.

17.

Nuclear magnetic resonance spectroscopic analysis of salivary metabolome in sarcoidosis.

Duchemann B, Triba MN, Guez D, Rzeznik M, Savarin P, Nunes H, Valeyre D, Bernaudin JF, Le Moyec L.

Sarcoidosis Vasc Diffuse Lung Dis. 2016 Mar 29;33(1):10-6.

PMID:
27055831
18.

Pulmonary Sarcoidosis.

Valeyre D, Bernaudin JF, Jeny F, Duchemann B, Freynet O, Planès C, Kambouchner M, Nunes H.

Clin Chest Med. 2015 Dec;36(4):631-41. doi: 10.1016/j.ccm.2015.08.006. Review.

PMID:
26593138
19.

Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy.

Kossai M, Duchemann B, Boutros C, Caramella C, Hollebecque A, Angevin E, Gazzah A, Bahleda R, Ileana E, Massard C, Vielh P, Soria JC, Besse B.

Lung Cancer. 2015 Sep;89(3):306-10. doi: 10.1016/j.lungcan.2015.06.014. Epub 2015 Jun 22.

PMID:
26160757
20.

Therapeutic management of ALK+ nonsmall cell lung cancer patients.

Duchemann B, Friboulet L, Besse B.

Eur Respir J. 2015 Jul;46(1):230-42. doi: 10.1183/09031936.00236414. Epub 2015 Apr 30. Review.

21.

Laryngeal sarcoidosis: a case-control study.

Duchemann B, Lavolé A, Naccache JM, Nunes H, Benzakin S, Lefevre M, Kambouchner M, Périé S, Valeyre D, Cadranel J.

Sarcoidosis Vasc Diffuse Lung Dis. 2014 Oct 20;31(3):227-34.

PMID:
25363223
22.

Epidemiology of idiopathic pulmonary fibrosis in Europe--an update.

Annesi-Maesano I, Nunes H, Duchemann B, Valeyre D, Agabiti N, Saltini C, Porretta MA.

Sarcoidosis Vasc Diffuse Lung Dis. 2013 Sep 1;30 Suppl 1:6-12.

PMID:
24081238
23.

[Hypersensitivity to radiation therapy in a patient with tuberous sclerosis: biological considerations about a clinical case].

Duchemann B, Wong S, Baruch-Hennequin V, Rivera S, Quero L, Hennequin C.

Cancer Radiother. 2013 Feb;17(1):50-3. doi: 10.1016/j.canrad.2012.11.001. Epub 2012 Dec 25. French. Erratum in: Cancer Radiother. 2013 Jul-Aug;17(4):334. Duchemain, B [corrected to Duchemann, B].

PMID:
23270679
24.

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, Giri U, Peyton M, Fan YH, Diao L, Masrorpour F, Shen L, Liu W, Duchemann B, Tumula P, Bhardwaj V, Welsh J, Weber S, Glisson BS, Kalhor N, Wistuba II, Girard L, Lippman SM, Mills GB, Coombes KR, Weinstein JN, Minna JD, Heymach JV.

Cancer Discov. 2012 Sep;2(9):798-811. doi: 10.1158/2159-8290.CD-12-0112. Epub 2012 Sep 6.

25.

[Focus on targeting the Ras-MAPK pathway: the Mek inhibitors].

Baldini C, Duchemann B, Hollebecque A, Routier É, Varga A, Gazzah A, Bahleda R, Besse B, Soria JC, Massard C.

Bull Cancer. 2012 Sep;99(9):865-74. doi: 10.1684/bdc.2012.1632. Review. French.

Supplemental Content

Loading ...
Support Center